Adverse reactions during biological therapy for psoriasis: Results of a survey of the Spanish Psoriasis Group;Efectos adversos observados durante la terapia biológica en la psoriasis. Resultados de una encuesta al Grupo Español de Psoriasis

Actas Dermo-Sifiliograficas

Volumn 101, Issue 2, 2010, Pages 156-163

  Sanchez Regana M ^a   Dilme E ^a   Puig, Ll ^b   Bordas, X ^c   Carrascosa, J M ^d   Ferran, M ^e   Herranz, P ^f   Garcia Bustinduy M ^g   Lopez Estebaranz J L ^h   Alsina, M ⁱ   Rodriguez M A ^j   Ribera, M ^d   Fernandez Lopez E ^k   Moreno, J C ^l   Belinchon Romero I ^m   Vidal, D ⁿ  

^a HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^h HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j HOSPITAL DE LEÓN   (Spain)

^k HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^l HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^m HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

ⁿ HOSPITAL DOS DE MAIG   (Spain)

more..

Author keywords

Adverse reactions; Biologic agents; Psoriasis; Safety; Survey

Indexed keywords

ADALIMUMAB; EFALIZUMAB; ETANERCEPT; INFLIXIMAB;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BICARBONATE BLOOD LEVEL; BLOOD EXAMINATION; BRONCHITIS; CELLULITIS; CEREBROVASCULAR ACCIDENT; CHICKENPOX; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EXTERNAL OTITIS; FACE ERYTHEMA; FATTY ACID BLOOD LEVEL; FURUNCULOSIS; GASTROENTERITIS; HEART PALPITATION; HERPES ZOSTER; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INFECTION; LABORATORY TEST; LEUKOCYTOSIS; LUNG ABSCESS; LUNG TUBERCULOSIS; MASTOIDITIS; MONOCYTOSIS; NAUSEA; PANCYTOPENIA; PAROTITIS; PERIANAL ABSCESS; PHARYNGITIS; PNEUMONIA; PROSTATITIS; PRURITUS; PSORIASIS; PYELONEPHRITIS; RASH; REBOUND; SEZARY CELL; SIDE EFFECT; SINUSITIS; STRIDOR; THORAX PAIN; TOOTH INFECTION; TRIACYLGLYCEROL BLOOD LEVEL; ULCER; URINARY TRACT INFECTION; URTICARIA;

EID: 77649163793     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S1578-2190(10)70602-8     Document Type: Article

References (20)

1. Ferrándiz C. Nuevos tratamientos en la psoriasis. Med Clin (Barc) 129 (2007) 377-378
2. Rapp S.R., Feldman S.R., Exum M.L., Fleisxe Jr. A.B., and Reboussin D.M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41 3 Pt 1 (1999) 401-407
3. Sterry W., Baker J., Boehncke W.H., Bos J.D., Chimenti S., Christophers E., et al. Biological therapies in the systemic management of psoriasis; International Consensus Conference. Br J Dermatol 151 (2004) 3-17
4. Thaci D. Long-term data in the treatment of psoriasis. Br J Dermatol 159 Suppl 2 (2008) 18-24
5. Gamo R., and López -Estebaranz J.L. Terapia biológica y psoriasis. Actas Dermosifiliogr 97 (2006) 1-17
6. Puig L., Carrascosa J.M., Daudén E., Sánchez-Carazo J.L., Ferrándiz C., Sánchez- Regaña M., et al. Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos. Actas Dermosifiliogr 100 (2009) 386-413
7. Leonardi C., Menter A., Hamilton T., Caro I., Xing B., and Gottlieb A.B. Efalizumab: results of a 3-year continous dosing study for the long-term control of psoriasis. Br J Dermatol 158 (2008) 1107-1116
8. Costanzo A., Peris K., Talamonti M., Di Cesare A., Concetta Fargnoli M., Botti E., et al. Long-term treatment of plaque psoriasis with efalizumab: an italian experience. Br J Dermatol 156 Suppl 2 (2007) 17-23
9. Antoniou C., Stefanaki I., Stratigos A., Avgerinou G., Stavropoulos P., Potouridou I., et al. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital. Br J Dermatol 156 Suppl 2 (2007) 12-16
10. Selenko-Gebauer N., Karlhoer F., and Stingl G. Efalizumab in routine use: a clinical experience. Br J Dermatol 156 Suppl 2 (2007) 1-6
11. Kragballe K. Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark. Br J Dermatol 156 Suppl 2 (2007) 7-11
12. Gottlieb A.B., Leonardi C.L., and Goffe B.S. Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy databse. J Am Acad Dermatol 54 (2006) S92-S100
13. Tyring S., Gorgon K.B., Poulin Y., Langley R.G., Gottlieb A.B., Dunn M., et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 143 (2007) 719-726
14. Ortonne J.P., Griffiths C., Daudén E., Strohal R., Robertson D., Pedersen R., et al. Comparación de la eficacia y seguridad del tratamiento continuo e intermitente con etanercept en pacientes con psoriasis moderada a grave durante 54 semanas: estudio CRYSTEL. Expert Rev Dermatol 3 (2008) 657-666
15. Ko J.M., Gottlieb A.B., and Kerbleski J.F. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat 20 (2009) 100-108
16. Reich K., Griffiths C., Barber J., Chimenti S., Daudén E., Giannetti A., et al. Recomendations for the long -term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology 217 (2008) 268-275
17. Puig L., Sáez E., Lozano M.J., Bordas X., Carrascosa J.M., Gallardo F., et al. Reacciones a la infusión de infliximab en pacientes dermatológicos. Actas Dermosifiliogr 100 (2009) 103-112
18. Warren R.B., Brown B.C., Lavery D., Ashcroft D.M., and Griffiths C.E.M. Biologic therapies for psoriasis: practical experiencie n a UK tertiary referral centre. Br J Dermatol 160 (2008) 162-169
19. Saurat J.H., Stingl G., Dubertret L., Papp K., Langley R.G., Ortonne J.P., et al. Efficacy and safety results from the comparative study of adalimumab (HUMIRA) versus methotrexate versus placebo in psoriasis patients (CHAMPION). Br J Dermatol 158 (2008) 558-566
20. Gordon K.B., Langley R.G., Leonardi C., Toth D., Menter M.A., Kang S., et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55 (2006) 598-606